Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organon (GB:0A9W)
LSE:0A9W
Organon (0A9W) Share Price & Analysis
0 Followers
0A9W Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.73 - $22.95
Previous Close$18.35
Volume2.46K
Average Volume (3M)3.07K
Market Cap
$4.73B
Enterprise Value$12.80B
Total Cash (Recent Filing)$693.00M
Total Debt (Recent Filing)$8.76B
Price to Earnings (P/E)N/A
Beta1.32
Next EarningsN/A
EPS EstimateN/A
Last Dividend Ex-Date
Feb 23, 2024Dividend Yield6.05%
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume3,072
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.04
Enterprise Value/Gross Profit3.42
Enterprise Value/Ebitda14.65
Forecast
1Y Price Target
$19.80Price Target Upside8.26% Upside
Rating ConsensusHold
Number of Analyst Covering5
Organon News
PremiumCompany Announcements
Organon & Co. Is Worried About This – Should You Be Worried Too?
PremiumCompany Announcements
Organon Reports Quarterly and Annual Financial Results
PremiumThe Fly
Organon rises 11.1%Bulls Say, Bears Say
Bulls Say
Dividend PolicyBiosimilars outperformed and free cash flow was stronger than expected, prompting management to express their commitment to the dividend.
Financial PerformanceOGN shares outperformed driven by a combination of factors including delivery of solid 4Q results across all three business segments.
Guidance UpdateUpdated FY24 guidance included an improvement to EBITDA margin expectations due to OPEX discipline.
Bears Say
Portfolio UpdatesThe absence of significant updates to the company's product portfolio in the near term may lead to investor concerns and downward pressure on the stock.
Research And DevelopmentReductions in R&D spending could delay the acquisition of essential assets, potentially affecting the stock as it approaches the Nexplanon loss of exclusivity period.
Revenue EstimatesAnalyst expects lower revenue estimates for Nexplanon and Hadlima, which could negatively impact the stock performance.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.73% Other Institutional Investors
98.27% Public Companies and
Individual Investors
0A9W FAQ
What was Organon’s price range in the past 12 months?
Organon lowest share price was $10.73 and its highest was $22.95 in the past 12 months.
What is Organon’s market cap?
Currently, no data Available
When is Organon’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Organon’s earnings last quarter?
Currently, no data Available
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Undervalued.
Does Organon pay dividends?
Organon pays a Quarterly dividend of $0.28 which represents an annual dividend yield of 6.05%. See more information on Organon dividends here
What is Organon’s EPS estimate?
Organon’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Organon have?
Currently, no data Available
What happened to Organon’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Organon?
Among the largest hedge funds holding Organon’s share is Slate Path Capital LP. It holds Organon’s shares valued at 52M.
---
Organon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.80 (8.26% Upside)
$19.80 (8.26% Upside)
Blogger Sentiment
Bullish
GB:0A9W Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $49.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.07%
Trailing 12-Months
Company Description
Organon
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
---
0A9W Stock 12 Months Forecast
Average Price Target
$19.80
▲(8.26% Upside)
Technical Analysis
Best Analysts Covering 0A9W
1 Year
1 Year Success Rate
5/5 ratings generated profit
1 Year Average Return
+14.44%
reiterated a buy rating 3 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +14.44% per trade.
---